1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novozymes A/S
  6. Summary
    NZYM B   DK0060336014

NOVOZYMES A/S

(NZYM B)
  Report
Real-time Estimate Cboe Europe  -  10:14 2022-08-10 am EDT
440.00 DKK   +1.80%
07/27NOVOZYMES A/S : New yeast innovations deliver unparalleled performance for bioenergy industry
PU
07/15Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost
GL
07/15Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
452.9(c) 432.1(c) 435.5(c) 432.2(c) 439.3 Last
274 910 241 504 356 177 208 471 105 050 Volume
+0.51% -4.59% +0.79% -0.76% +1.64% Change
More quotes
Estimated financial data (e)
Sales 2022 16 879 M 2 319 M 2 319 M
Net income 2022 3 157 M 434 M 434 M
Net Debt 2022 5 779 M 794 M 794 M
P/E ratio 2022 37,9x
Yield 2022 1,33%
Sales 2023 17 771 M 2 442 M 2 442 M
Net income 2023 3 494 M 480 M 480 M
Net Debt 2023 6 197 M 851 M 851 M
P/E ratio 2023 34,0x
Yield 2023 1,43%
Capitalization 119 B 16 407 M 16 407 M
EV / Sales 2022 7,42x
EV / Sales 2023 7,07x
Nbr of Employees 6 641
Free-Float 72,5%
More Financials
Company
Novozymes A/S is the world's leading producer of enzymes and microorganisms for industrial companies. Net sales break down by market as follows: - industry of cleaning and household maintenance products (31.8%); - food industry and human health (23.2%); - bioenergy (18.1%); - technical and cereal industries (15%): microorganisms used in the field of wastewater treatment, technical enzymes intended for the... 
Sector
Specialty Chemicals
Calendar
08/11Earnings Release
More about the company
Ratings of Novozymes A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about NOVOZYMES A/S
07/27NOVOZYMES A/S : New yeast innovations deliver unparalleled performance for bioenergy indus..
PU
07/15Novozymes plan to further increase prices across the portfolio in response to the signi..
GL
07/15Novozymes plan to further increase prices across the portfolio in response to the signi..
AQ
06/29Novozymes' financial calendar 2023
GL
06/27Transactions under Novozymes' stock buyback program
GL
06/27Transactions under Novozymes' stock buyback program
GL
06/27NOVOZYMES A/S : Share buyback
CO
06/21Biotalys Seeks To Expand Proprietary Biofungicide Use With Denmark's Novozymes
MT
06/21Biotalys and Novozymes Enter into Partnership to Expand Opportunities for Evoca™
CI
06/20Transactions under Novozymes' stock buyback program
GL
06/20Transactions under Novozymes' stock buyback program
GL
06/20NOVOZYMES A/S : Share buyback
CO
06/17TRANSCRIPT : Novozymes A/S - Special Call
CI
06/16Novozymes and AgroFresh form partnership to unlock the potential of biotechnology to im..
AQ
06/15AgroFresh Solutions, Novozymes to Partner on Post-Harvest Food Quality
MT
More news
News in other languages on NOVOZYMES A/S
07/29SYMRISE IM FOKUS : Gut gewappnet gegen Wirtschaftsschwäche - Übernahmekandidat?
07/01BOLSA DE MADRID : Esta vez no es diferente
07/01Cette fois, c'est pas différent
07/01AVIS D'ANALYSTES DU JOUR : TotalEnergies, UBS, Amundi, Umicore, Sika, FDJ, Solvay, OVH...
06/21Bel20 sluit hoger met hulp van Argenx
More news
Analyst Recommendations on NOVOZYMES A/S
More recommendations
Chart NOVOZYMES A/S
Duration : Period :
Novozymes A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOZYMES A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 432,20 DKK
Average target price 454,63 DKK
Spread / Average Target 5,19%
EPS Revisions
Managers and Directors
Ester Baiget President & Chief Executive Officer
Lars Green Chief Financial Officer & Executive Vice President
J°rgen Buhl Rasmussen Chairman
Claus Crone Fuglsang Chief Scientific Officer & Executive VP
Graziela Chaluppe dos Santos Malucelli Chief Operating Officer & Executive VP